Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes MellitusComparison with Other Oral Antihyperglycaemic Agents

被引：0
|
作者：
Giuseppe Derosa
机构：
[1] University of Pavia,Department of Internal Medicine and Therapeutics
来源：
Drugs | 2010年 / 70卷
关键词：
Metformin; Rosiglitazone; Pioglitazone; Acarbose; Sitagliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Diabetes mellitus is a debilitating disease that is estimated to affect 366 million people by the year 2030. Type 2 diabetes mellitus (T2DM) is characterized by a progressive decline in pancreatic β-cell function and increased insulin resistance, and accounts for approximately 90% of people with diabetes. Oral antihyperglycaemic agents are extensively used in the treatment of T2DM. Thiazolidinediones are insulin sensitizers developed specifically for T2DM, which act via activation of peroxisome proliferator-activated receptors (PPARs). Pioglitazone is a thiazolidinedione that displays high affinity for PPARγ1 and PPARγ2, which are predominately expressed in adipose tissue.
引用
收藏
页码：1945 / 1961
页数：16
相关论文
共 50 条
  • [1] Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus Comparison with Other Oral Antihyperglycaemic Agents
    Derosa, Giuseppe
    [J]. DRUGS, 2010, 70 (15) : 1945 - 1961
  • [2] Oral antihyperglycaemic agents in type 2 diabetes mellitus
    Smith, Haley
    [J]. SA PHARMACEUTICAL JOURNAL, 2014, 81 (03) : 10 - 14
  • [3] Time to next therapy for patients with type 2 diabetes in the UK: canagliflozin compared with other antihyperglycaemic agents
    Diels, J.
    Schubert, A.
    Hamilton, G.
    [J]. DIABETOLOGIA, 2017, 60 : S19 - S19
  • [4] Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus
    Romera, Irene
    Ampudia-Blasco, Francisco Javier
    Perez, Antonio
    Arino, Bernat
    Pfarr, Egon
    Kis, Sanja Giljanovic
    Naderali, Ebrahim
    [J]. ENDOCRINOLOGIA Y NUTRICION, 2016, 63 (10): : 519 - 526
  • [5] Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents
    Chu, JW
    Abbasi, F
    McLaughlin, TL
    Lamendola, C
    Schaaf, P
    Carlson, TH
    Leary, ET
    Reaven, GM
    [J]. DIABETES OBESITY & METABOLISM, 2003, 5 (05): : 333 - 337
  • [6] Risk of prostatitis in patients with type 2 diabetes: a retrospective database study of canagliflozin vs other antihyperglycaemic agents
    Yuan, Z.
    Jeffcoat, C.
    Ali, R. S.
    Ryan, P.
    Sena, A.
    Schuemie, M.
    Fonseca, S.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S352 - S352
  • [7] Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus who were, or were not, on antihyperglycaemic agents at screening
    Gonzalez-Galvez, G.
    Jodar, E.
    Kim, K.
    Alba, M.
    Tong, C.
    Meininger, G.
    [J]. DIABETOLOGIA, 2014, 57 : S347 - S348
  • [8] Pioglitazone and oral cancer risk in patients with type 2 diabetes
    Tseng, Chin-Hsiao
    [J]. ORAL ONCOLOGY, 2014, 50 (02) : 98 - 103
  • [9] Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
    Rosenstock, J.
    Baron, M. A.
    Camisasca, R. -P.
    Cressier, F.
    Couturier, A.
    Dejager, S.
    [J]. DIABETES OBESITY & METABOLISM, 2007, 9 (02): : 175 - 185
  • [10] Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo
    Lavernia, Frank
    Blonde, Lawrence
    [J]. POSTGRADUATE MEDICINE, 2020, 132 : 15 - 25
12345